As prescribing rates climb, awareness of GLP-1 dermatologic effects becomes essential for safe and informed practice
Similarly, JP Morgan 6 forecasts that the use of GLP-1RA drugs for both weight loss and diabetes indications in the U.S
Lilly has now submitted a rolling submission of a new drug application (NDA) for tirzepatide in adults with obesity or overweight
Most clinical guidance recommends: At 3 months: A1c recheck (HbA1c reflects the prior 3-month average, making this the earliest timepoint for meaningful assessment of glycemic response), metabolic panel if any GI side effects were significant At 6 months: Full panel repeat A1c, CMP, lipids, CBC to document treatment response comprehensively Annually: Full panel plus thyroid function, B12, and any additional markers relevant to your individual health picture If you experience severe or persistent gastrointestinal side effects, signs of dehydration, unusual fatigue, or any concerning symptoms, kidney function should be rechecked without waiting for a scheduled interval
